Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 630 participants.
Also called NCT01192724
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 630 participants
- Sponsor
- Registry
-
NCT01192724
-
- Other papers using this trial's data
- Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01192724. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation
- Acronym
- ABCD
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Cilostazol
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct01192724- Content hash
9fc460e6a925b77eb0722f70638a7c2c3eef47816ca34cff339f6f0bb1281ae8